Stock DNA
Pharmaceuticals & Biotechnology
CAD 18 Million ()
NA (Loss Making)
NA
0.00%
-0.81
53.60%
-2.01
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-21.43%
0%
-21.43%
6 Months
-31.25%
0%
-31.25%
1 Year
-26.67%
0%
-26.67%
2 Years
-8.33%
0%
-8.33%
3 Years
22.22%
0%
22.22%
4 Years
-31.25%
0%
-31.25%
5 Years
-50.0%
0%
-50.0%
MedX Health Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.09%
EBIT Growth (5y)
0.33%
EBIT to Interest (avg)
-2.76
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.79
Sales to Capital Employed (avg)
-0.30
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.01
EV to EBIT
-8.43
EV to EBITDA
-8.56
EV to Capital Employed
-15.20
EV to Sales
24.86
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-0.90
-0.70
-28.57%
Interest
0.40
0.20
100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.30
-0.90
-44.44%
Operating Profit Margin (Excl OI)
-10,528.00%
-7,059.40%
-346.86%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 0.00% vs -50.00% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -44.44% vs 35.71% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.50
0.50
Operating Profit (PBDIT) excl Other Income
-2.30
-3.00
23.33%
Interest
1.30
2.20
-40.91%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.70
-4.60
19.57%
Operating Profit Margin (Excl OI)
-4,704.40%
-6,632.50%
192.81%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 19.57% vs 9.80% in Dec 2023
About MedX Health Corp. 
MedX Health Corp.
Pharmaceuticals & Biotechnology
MedX Health Corp. is a medical device company. The Company is focused on research, development, manufacturing and distribution of phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode (LED). Its products are offered to the rehabilitation market for treating pain, tissue damage, swelling and inflammation. It offers SIAscopy, which is a medical device that is used to scan suspicious moles and lesions. Its SIMSYS-MoleMate Skin Imaging System is a non-invasive skin screening procedure for moles and lesions. Its SIMSYS uses SIAscopy providing detail and information from approximately two millimeters beneath the skin. Its MoleMate is a non-invasive, rapid and painless screening device that has been designed with and for general practitioners and skin specialists. Its SIAMETRICS allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, hemoglobin and collagen in living human skin.
Company Coordinates 
Company Details
1495 Bonhill Road, Unit 1 , MISSISSAUGA ON : L5T1M2
Registrar Details






